Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

Published:2023-07 Issue:7 Volume:29 Page:449.e1-449.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Ahmed Nausheen^ORCID,Wesson William^ORCID,Mushtaq Muhammad Umair^ORCID,Porter David L.,Nasta Sunita D.,Brower Jamie^ORCID,Bachanova Veronika,Hu Marie^ORCID,Nastoupil Loretta J.^ORCID,Oluwole Olalekan O.,Patel Vivek G.,Oliai Caspian^ORCID,Riedell Peter A.^ORCID,Bishop Michael R.,Shah Gunjan L.^ORCID,Perales Miguel-Angel,Schachter Levanto,Maziarz Richard T.^ORCID,McGuirk Joseph P.^ORCID

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference33 articles.

1. First-ever CAR T-cell therapy approved in US;Cancer Discov,2017

2. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

3. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial;Jacobson;Lancet Oncol,2022

4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

5. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention;Blood Advances;2024-08-15

2. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers;Frontiers in Immunology;2024-05-08

3. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations;Clinical Hematology International;2024-04-09

4. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?;Clinical Hematology International;2024-03-13

5. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy;Transplantation and Cellular Therapy;2024-02